Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Aug;78(4):546–549. doi: 10.1038/bjc.1998.530

Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Réseau Comète INSERM.

R Bonacci 1, A Gigliotti 1, E Baudin 1, N Wion-Barbot 1, P Emy 1, M Bonnay 1, A F Cailleux 1, I Nakib 1, M Schlumberger 1
PMCID: PMC2063075  PMID: 9716042

Abstract

Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m(-2) day(-1) on days 1-3) and cisplatin (100 mg m(-2) day(-1) on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels >14 mg l(-1). Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.

Full text

PDF
546

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertagna C., Orth D. N. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med. 1981 Nov;71(5):855–875. doi: 10.1016/0002-9343(81)90384-3. [DOI] [PubMed] [Google Scholar]
  2. Boven E., Vermorken J. B., van Slooten H., Pinedo H. M. Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review. Cancer. 1984 Jan 1;53(1):26–29. doi: 10.1002/1097-0142(19840101)53:1<26::aid-cncr2820530107>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  3. Bukowski R. M., Wolfe M., Levine H. S., Crawford D. E., Stephens R. L., Gaynor E., Harker W. G. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1993 Jan;11(1):161–165. doi: 10.1200/JCO.1993.11.1.161. [DOI] [PubMed] [Google Scholar]
  4. Chun H. G., Yagoda A., Kemeny N., Watson R. C. Cisplatin for adrenal cortical carcinoma. Cancer Treat Rep. 1983 May;67(5):513–514. [PubMed] [Google Scholar]
  5. Didolkar M. S., Bescher R. A., Elias E. G., Moore R. H. Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer. 1981 May 1;47(9):2153–2161. doi: 10.1002/1097-0142(19810501)47:9<2153::aid-cncr2820470908>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  6. Haak H. R., Hermans J., van de Velde C. J., Lentjes E. G., Goslings B. M., Fleuren G. J., Krans H. M. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994 May;69(5):947–951. doi: 10.1038/bjc.1994.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hesketh P. J., McCaffrey R. P., Finkel H. E., Larmon S. S., Griffing G. T., Melby J. C. Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep. 1987 Feb;71(2):222–224. [PubMed] [Google Scholar]
  8. Hutter A. M., Jr, Kayhoe D. E. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med. 1966 Oct;41(4):581–592. doi: 10.1016/0002-9343(66)90220-8. [DOI] [PubMed] [Google Scholar]
  9. Icard P., Louvel A., Chapuis Y. Survival rates and prognostic factors in adrenocortical carcinoma. World J Surg. 1992 Jul-Aug;16(4):753–758. doi: 10.1007/BF02067377. [DOI] [PubMed] [Google Scholar]
  10. Jensen J. C., Pass H. I., Sindelar W. F., Norton J. A. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg. 1991 Apr;126(4):457–461. doi: 10.1001/archsurg.1991.01410280059008. [DOI] [PubMed] [Google Scholar]
  11. Johnson D. H., Greco F. A. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer. 1986 Nov 15;58(10):2198–2202. doi: 10.1002/1097-0142(19861115)58:10<2198::aid-cncr2820581006>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  12. Luton J. P., Cerdas S., Billaud L., Thomas G., Guilhaume B., Bertagna X., Laudat M. H., Louvel A., Chapuis Y., Blondeau P. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990 Apr 26;322(17):1195–1201. doi: 10.1056/NEJM199004263221705. [DOI] [PubMed] [Google Scholar]
  13. Pommier R. F., Brennan M. F. An eleven-year experience with adrenocortical carcinoma. Surgery. 1992 Dec;112(6):963–971. [PubMed] [Google Scholar]
  14. Schlumberger M., Brugieres L., Gicquel C., Travagli J. P., Droz J. P., Parmentier C. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer. 1991 Jun 15;67(12):2997–3000. doi: 10.1002/1097-0142(19910615)67:12<2997::aid-cncr2820671211>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  15. Tattersall M. H., Lander H., Bain B., Stocks A. E., Woods R. L., Fox R. M., Byrne E., Trotten J. R., Roos I. Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust. 1980 May 3;1(9):419–421. doi: 10.5694/j.1326-5377.1980.tb134997.x. [DOI] [PubMed] [Google Scholar]
  16. van Slooten H., van Oosterom A. T. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep. 1983 Apr;67(4):377–379. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES